Antares Pharma Inc. (ATRS)

3.47
0.17 5.20
NASDAQ : Health Technology
Prev Close 3.30
Open 3.27
Day Low/High 3.25 / 3.39
52 Wk Low/High 2.53 / 3.96
Volume 265.52K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 163.06M
Market Cap 539.74M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Antares' Otrexup Approval Was Easy, Selling Drug Will be Hard

Antares' Otrexup Approval Was Easy, Selling Drug Will be Hard

Doctors are unlikely to embrace Otrexup for rheumatoid arthritis patients without more efficacy data.

OTREXUP™ (methotrexate) Injection Approved By FDA A New Treatment For Adults With Rheumatoid Arthritis, Children With Polyarticular Idiopathic Arthritis, And Adults With Psoriasis

OTREXUP™ (methotrexate) Injection Approved By FDA A New Treatment For Adults With Rheumatoid Arthritis, Children With Polyarticular Idiopathic Arthritis, And Adults With Psoriasis

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of OTREXUP ™ (methotrexate) injection by the U.

4 Biotech Stocks Under $10 Making Moves

4 Biotech Stocks Under $10 Making Moves

Keep these biotech stocks on your radar.

First Week Of May 2014 Options Trading For Antares Pharma (ATRS)

First Week Of May 2014 Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options begin trading this week, for the May 2014 expiration.

Antares Pharma Announces First Patients Dosed In VIBEX™ QS T Study Evaluating Testosterone Deficient Males

Antares Pharma Announces First Patients Dosed In VIBEX™ QS T Study Evaluating Testosterone Deficient Males

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patients have been dosed in a clinical study evaluating testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100...

Ratings Changes Today

Upgrades: ATRS, BREW, OFG Downgrades: BBGI, MS, NRP, PERY, UEPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Stocks Under $10 Moving Higher

3 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Antares Pharma Reports Second Quarter 2013 Operating And Financial Results

Antares Pharma Reports Second Quarter 2013 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the second quarter ended June 30, 2013.

Antares Pharma To Host Second Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma To Host Second Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2013 financial results before the market opens on Wednesday, August 7, 2013, and host a conference call shortly thereafter at 8:30...

Antares Pharma Welcomes Robert P. Roche Jr. To Board Of Directors

Antares Pharma Welcomes Robert P. Roche Jr. To Board Of Directors

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the election of Robert P.

First Week Of ATRS September 21st Options Trading

First Week Of ATRS September 21st Options Trading

Investors in Antares Pharma Inc. saw new options become available this week, for the September 21st expiration.

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.

Antares Pharma Announces The Issuance Of A New U. S. Patent For OTREXUP™

Antares Pharma Announces The Issuance Of A New U. S. Patent For OTREXUP™

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Issuance from the U.

Subcutaneous, Self-Administered Methotrexate For Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard Of Care

Subcutaneous, Self-Administered Methotrexate For Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard Of Care

Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the...

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Antares Pharma Reports Fourth Quarter And Full Year 2012 Operating And Financial Results

Antares Pharma Reports Fourth Quarter And Full Year 2012 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2012.

Antares Pharma To Host Fourth Quarter 2012 Call

Antares Pharma To Host Fourth Quarter 2012 Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2012 financial results before the market opens on Wednesday, March 13, 2013, and host a conference call shortly thereafter at 8:30...

Antares Pharma Announces FDA Acceptance Of New Drug Application For OTREXUP™

Antares Pharma Announces FDA Acceptance Of New Drug Application For OTREXUP™

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the New Drug Application (NDA) for OTREXUP™, a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet™ technology, ...

Antares Pharma To Present At The Cowen And Company 33rd Annual Healthcare Conference

Antares Pharma To Present At The Cowen And Company 33rd Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma To Participate In The 2013 RBC Capital Markets’ Healthcare Conference

Antares Pharma To Participate In The 2013 RBC Capital Markets’ Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

'Mad Money' Lightning Round: Cisco Is Good

'Mad Money' Lightning Round: Cisco Is Good

Cramer also likes Total but he's not crazy about Antares Pharma, Chesapeake Energy or EMC.

Cramer's 'Mad Money' Recap: Lose the Gloom and Doom

Cramer's 'Mad Money' Recap: Lose the Gloom and Doom

Investors need to ignore the bad news because the time to invest is now, Cramer said.

Antares Pharma Announces Submission Of New Drug Application For OTREXUP™

Antares Pharma Announces Submission Of New Drug Application For OTREXUP™

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.

Antares Pharma To Present At The Oppenheimer 23rd Annual Healthcare Conference

Antares Pharma To Present At The Oppenheimer 23rd Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

'Mad Money' Lightning Round: Take the Money and Run From AEO

'Mad Money' Lightning Round: Take the Money and Run From AEO

Cramer also says to avoid Antares Pharma and Frontier Communications but would go with Apple and Linn Energy.

Cramer's 'Mad Money' Recap: Reasons to Worry

Cramer's 'Mad Money' Recap: Reasons to Worry

The optimists think going over the 'fiscal cliff' is no big deal. Cramer thinks they're dead wrong.

Antares Pharma Announces Positive Results From Final MTX Medi-Jet™ Clinical Study

Antares Pharma Announces Positive Results From Final MTX Medi-Jet™ Clinical Study

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from an open-label, randomized, crossover study comparing the systemic availability of MTX Medi-Jet to oral methotrexate (MTX) in adult patients with...

Antares Pharma To Present At The Jefferies 2012 Global Healthcare Conference

Antares Pharma To Present At The Jefferies 2012 Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Reports Third Quarter 2012 Financial And Operating Results

Antares Pharma Reports Third Quarter 2012 Financial And Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the third quarter ended September 30, 2012.

TheStreet Quant Rating: C (Hold)